Sequencing Radium-223 and Lutetium-177 PSMA Therapy in mCRPC Management: Insights from the RaLu Trial
/in Clinical Trial, Metastatic, Phase 1/by MaxB7-H4-Targeting Antibody-Drug Conjugate, LNCB74, Gets Green Light for Clinical Trials for Solid Tumors
/in Clinical Trial, Phase 1/by MaxOP-3136: New Drug Receives FDA Clearance to Begin Clinical Trials
/in Clinical Trial, Metastatic, Phase 1/by MaxA New Dawn for Disease Treatment: Combining mRNA and RNAi Therapies
/in CRISPR, Preclinical Research/by MaxNewsletter 4
/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Here I am with the fourth newsletter from the site. In the next days I will be reporting some (hopefully) good news from an immune oncology symposium, fingers crossed! Some of the subscribers suggested me to reactivate the donations button, do you […]
Matching-Adjusted Comparison of PARPi Therapies for mCRPC: Talazoparib + Enzalutamide Wins
/in Clinical Trial, Metastatic, Observational, Post-hoc, Retrospective studies/by MaxMapping the Gut: A New Atlas Illuminates the Path to Understanding and Treating Cancer (and other diseases)
/in Not PCa related, Preclinical Research/by MaxPreclinical: A More Efficient and Selective Path to Anti-Cancer Drugs
/in Preclinical Research/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Dietary Fat and Survival After Nonmetastatic Prostate Cancer September 7, 2026
- Phase 1 Trial: IL‑18–Armored STEAP1 CAR T Cells for Metastatic Castration‑Resistant Prostate Cancer September 7, 2026
- Newsletter 36/2026 September 6, 2026
- De‑escalation therapy in metastatic prostate cancer: can some men safely stop ADT + ARPI after a deep response? September 4, 2026